コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ivation, and increased polyubiquitination of TNF receptor-associated factors.
5 osome-linked IAP, Bcl-2, Bcl-x(L), Bfl-1/A1, TNF receptor-associated factor 1, and cellular Fas-assoc
7 bitor of apoptosis protein (c-IAP1), c-IAP2, TNF receptor-associated factor-1 (TRAF-1), TRAF-2, B-cel
8 romosome-linked IAP (XIAP), Bcl-2, Bfl-1/A1, TNF receptor-associated factor-1 (TRAF1), and Fas-associ
11 B-inducing kinase-IKK was interrupted at the TNF receptor associated factor 2 and NF-kappa B-inducing
12 eptor 1-TNF receptor associated death domain-TNF receptor associated factor 2 NF-kappa B-inducing kin
14 , TNF receptor 2 (TNF-R2) interacts with the TNF receptor associated factors 2/1 (TRAF2/TRAF1) hetero
15 ding of CD154 (gp39, CD40L) to CD40 recruits TNF receptor- associated factor 2 (TRAF2) and TRAF3 to t
17 induces IRAK1 sumoylation in the presence of TNF receptor-associated factor 2 (TRAF2) and intracellul
18 B and JNK activity associated with increased TNF receptor-associated factor 2 (TRAF2) and NF-kappaB e
21 of the Fn14-TRAF domain site or depletion of TNF receptor-associated factor 2 (TRAF2) expression by s
23 In addition, we also demonstrated that the TNF receptor-associated factor 2 (TRAF2) plays little ro
27 we discovered that GAPDH interacts with the TNF receptor-associated factor 2 (TRAF2), a protein requ
28 and CD160 engagement induced recruitment of TNF receptor-associated factor 2 (TRAF2), but not TRAF3,
29 ptosis signal-regulating kinase 1 (ASK1) and TNF receptor-associated factor 2 (TRAF2), regulation of
30 aling by TRANCE-R appears to be dependent on TNF receptor-associated factor 2 (TRAF2), since JNK indu
31 aprolin (TTP) is Lys-63-polyubiquitinated by TNF receptor-associated factor 2 (TRAF2), suggesting a r
32 wn to be important for CD40 association with TNF receptor-associated factor 2 (TRAF2), TRAF3, and TRA
38 cells, along with the selective reduction of TNF receptor-associated factor 2 and impairment in the a
39 e/IkappaBalpha kinase was interrupted at the TNF receptor-associated factor 2 and NF-kappaB-inducing
41 d IL-6, and the cytoplasmic adaptor molecule TNF receptor-associated factor 2 is involved in both R-8
42 Tumor necrosis factor alpha (TNF-alpha) and TNF receptor-associated factor 2 protein were moderately
46 at beta-arrestin-1 is associated with TRAF2 (TNF receptor-associated factor 2), an adaptor protein of
47 osis protein 1, Bcl-2, Bcl-xL, survivin, and TNF receptor-associated factor 2), proliferation (cyclin
48 F-alpha induced the ubiquitination of TRAF2 (TNF receptor-associated factor 2), which interacts with
49 ter gene expression activated by TNF, TNFR1, TNF receptor-associated factor 2, and NF-kappaB-inducing
50 eptor, TNF receptor-associated death domain, TNF receptor-associated factor 2, NF-kappa B-inducing ki
51 e activated by receptor-interacting protein, TNF receptor-associated factor 2, NF-kappaB-inducing kin
52 IKK-beta, TNF receptor-associated factor 6, TNF receptor-associated factor 2, receptor-interacting p
53 ulin were related to increased expression of TNF receptor-associated factor 2, the product of an NF-k
54 These data suggest that TNFR1, through a TNF receptor-associated factor 2-NF-kappaB signaling pat
57 eptor 1/TNF receptor-associated death domain/TNF receptor-associated factor 2/NF-kappaB-inducing kina
58 cytoplasmic domain of CD40, while binding of TNF receptor-associated factors 2 and 3 is dispensable,
65 ere, we identify that tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) knockdown (KD)
68 paB regulator, TRAF2 (tumor necrosis factor (TNF) receptor-associated factor 2), as an oncogene that
69 (E2) Ubc13 for binding to the RING domain of TNF-receptor associated factor 2 (TRAF2), thereby inhibi
71 RADD (TNF receptor-associated death domain), TNF receptor-associated factor-2 (TRAF-2), the Ser/Thr k
72 ptor proteins, including the docking protein TNF receptor-associated factor-2 (TRAF-2), which is beli
76 both knockdowns reduce expression of TRAF2 (TNF receptor-associated factor-2) protein, and small int
77 IP (receptor-interacting protein), or TRAF2 (TNF receptor-associated factor-2) were caused by apoptog
78 hibitor of apoptosis-1), cIAP-2, and TRAF-2 (TNF receptor-associated factor-2)) in an NF-kappaB-depen
79 tor 1, TNF receptor-associated death domain, TNF receptor-associated factor-2, NF-kappaB-inducing kin
80 tor 1, TNF receptor-associated death domain, TNF receptor-associated factor-2, NF-kappaB-inducing kin
83 alterations of key regulators of NF-kappaB, TNF receptor associated factor 3 (TRAF3), and cylindroma
84 as used to explore the in vivo expression of TNF receptor-associated factor 3 (TRAF-3), a putative si
86 its additional signaling proteins, including TNF receptor-associated factor 3 (TRAF3) and TANK-bindin
87 D88 as a prototypical adaptor, we identified TNF receptor-associated factor 3 (TRAF3) as a new compon
89 vely regulated by the full-length isoform of TNF receptor-associated factor 3 (Traf3) as formation of
90 nonical NF-kappaB2 pathway and its component TNF receptor-associated factor 3 (TRAF3) by the VDRA par
94 athway signaling by promoting degradation of TNF receptor-associated factor 3 (Traf3), a potent inhib
95 , but not RANKL, increased OCP expression of TNF receptor-associated factor 3 (TRAF3), an adapter pro
96 d the effect of selective deletion in TEC of TNF receptor-associated factor 3 (TRAF3), an inhibitor o
97 volves degradation of an inhibitory protein, TNF receptor-associated factor 3 (TRAF3), but how this s
98 elated bone loss by promoting degradation of TNF receptor-associated factor 3 (TRAF3), levels of whic
103 onstrate that loss of tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3) results in con
104 in and failed to bind tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3), a TBK1 comple
105 uniparental disomy in tumor necrosis factor (TNF) receptor-associated factor 3 and TNFalpha-induced p
107 induces IDO and involves the recruitment of TNF receptor-associated factor-3 to the Toll-like recept
108 uous degradation by a tumor necrosis factor (TNF) receptor-associated factor-3 (TRAF3)-dependent E3 u
112 ownstream gene-TRAF4 (tumor necrosis factor [TNF] receptor associated-factor 4)-that functions in cel
113 Here, we identify tumor necrosis factor (TNF)-receptor-associated factor-4 (TRAF4) as a new targe
115 is inhibited by dominant negative mutants of TNF receptor-associated factor 5 (TRAF5), TRAF6, NF-kapp
117 found to activate NF-kappaB in concert with TNF receptor associated factor 6 (TRAF6), we propose tha
118 l analyses revealed that DAB2 interacts with TNF receptor-associated factor 6 (TRAF6) and attenuates
119 r set, we identified the E3 ubiquitin ligase TNF receptor-associated factor 6 (TRAF6) as a SOD1 inter
121 NKL-induced NF-kappaB activation and delayed TNF receptor-associated factor 6 (TRAF6) deubiquitinatio
122 completely understood, but ubiquitination of TNF receptor-associated factor 6 (TRAF6) has recently be
123 autoantigenic sperm protein (sNASP) binds to TNF receptor-associated factor 6 (TRAF6) in the resting
127 , NDPK-D was required for the recruitment of TNF receptor-associated factor 6 (TRAF6) to mitochondria
129 Upon LPS challenge, CREBH interacts with TNF receptor-associated factor 6 (TRAF6), an E3 ubiquiti
131 ptor (TIR) adaptor Myd88 adaptor-like (Mal), TNF receptor-associated factor 6 (TRAF6), and IkappaB ki
133 urthermore, NOSTRIN interacted directly with TNF receptor-associated factor 6 (TRAF6), leading to the
134 1 receptor-associated protein kinase (IRAK), TNF receptor-associated factor 6 (TRAF6), phosphatidylin
135 rectly interacting with the TRAF-C domain of TNF receptor-associated factor 6 (TRAF6), resulting in i
140 Lys-34 and required the E3 ubiquitin ligase TNF receptor-associated factor 6 after stimulation of ce
141 se-pair with sequences in the 3' UTRs of the TNF receptor-associated factor 6 and IL-1 receptor-assoc
142 ys-63-linked polyubiquitination at Lys-34 by TNF receptor-associated factor 6 and is thereby activate
143 nd prevents the dissociation of, IRAK-IRAK-4-TNF receptor-associated factor 6 from the TLR signaling
145 ependent upon binding of the adapter protein TNF receptor-associated factor 6 to the cytoplasmic doma
146 ase) and subsequently integrates with TRAF6 (TNF receptor-associated factor 6) and/or c-fos signaling
147 ukin-1 receptor-associated kinase)1/4-TRAF6 (TNF receptor-associated factor 6), leading to integrin a
148 d expression of the signal transducer TRAF6 (TNF receptor-associated factor 6), leading us to conside
149 e system of IKK complex activation by TRAF6 (TNF receptor-associated factor 6), we show that these pe
151 involving MyD88, IL-1R-associated kinase 1, TNF receptor-associated factor 6, and IkappaB kinase and
152 ts of myeloid differentiation protein, IRAK, TNF receptor-associated factor 6, and NF-kappaB-inducing
153 otein interactions with IKK-alpha, IKK-beta, TNF receptor-associated factor 6, TNF receptor-associate
154 leukin (IL)-1 receptor-associated kinase and TNF receptor-associated factor 6, two key adaptor/scaffo
155 luding MyD88, IL-1R-associated kinase 4, and TNF receptor-associated factor 6, while it inhibited the
158 t signaling by disrupting the recruitment of TNF receptor-associated factor 6/c-Src complex to lipid
159 s of NF-kB signaling, tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) and transformi
160 the molecular adaptor tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) exhibit a spec
163 es demonstrated that tumour necrosis factor (TNF) receptor-associated factor 6 (TRAF6) plays a key ro
164 estigated the role of tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6), an adaptor pr
165 Here we show that tumour necrosis factor (TNF) receptor-associated factor 6 (TRAF6), an adaptor pr
166 d kinase (IRAK-1) and tumor-necrosis factor (TNF) receptor-associated factor 6 (TRAF6), which are kno
167 We also found that tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6), which mediate
171 he CINC promoter by IL-17 in IEC-6 cells was TNF receptor-associated factor-6 (TRAF6), but not TRAF2,
172 r gene activity was 16-fold higher following TNF receptor-associated factor-6 transfection after IL-1
173 ly interacts with IL-1R-associated kinase-1, TNF receptor-associated factor-6, TGF-beta-activated kin
174 cells, is dependent upon a MyD88-dependent, TNF receptor-associated factor-6-independent signaling p
175 l survival by hindering interactions between TNF-receptor-associated factors, blocking their negative
177 te that cells lacking TRAF3, a member of the TNF receptor-associated factor family, are defective in
178 Here we identified mutations in TRAF3IP1 (TNF Receptor-Associated Factor Interacting Protein 1) in
179 mary gland identified tumor necrosis factor (TNF) receptor-associated factor-interacting protein (TRI
180 eptor, TNF receptor-associated death domain, TNF receptor-associated factor, NF-kappaB-inducing kinas
181 paB activation pathways, including the TRAF (TNF receptor-associated factor) proteins, IKK, NF-kappaB
183 NOPO is the Drosophila homolog of human TNF receptor associated factor (TRAF)-interacting protei
184 aling (SOCS) 3, B-cell CLL/lymphoma (BCL) 3, TNF receptor-associated factor (TRAF) 1, and TNFAIP3-int
185 ation and proteasome-mediated degradation of TNF receptor-associated factor (TRAF) 2 and TRAF6, which
186 of c-IAP1 is blocked upon coexpression with TNF receptor-associated factor (TRAF) 2, and this is ach
187 receptor-associated kinase (IRAK) 4, IRAK1, TNF receptor-associated factor (TRAF) 6, TGF-beta-activa
191 act directly with signaling molecules of the TNF receptor-associated factor (TRAF) family to activate
195 is: inhibitor of apoptosis(IAP)-1 and X-IAP, TNF receptor-associated factor (TRAF)-2, and factors OX4
196 rm prolactin receptors (PRLR-S), constrained TNF receptor-associated factor (TRAF)-dependent innate i
197 sponsible for noncanonical ubiquitination of TNF receptor-associated factor (TRAF)-family adapter pro
198 n-canonical K63-linked polyubiquitination of TNF receptor-associated factor (TRAF)-family adapter pro
199 HVEM activates NF-kappaB and AP-1 through a TNF receptor-associated factor (TRAF)-mediated mechanism
200 antiapoptotic factors Bcl-xL, A1/Bfl-1, and TNF receptor-associated factor (TRAF)1, all of which are
201 xpressing in B lymphocytes either Bcl-2 or a TNF receptor-associated factor (TRAF)2 mutant lacking th
202 receptor-associated death domain (TRADD), DN-TNF receptor-associated factor (TRAF)2, DN-receptor-inte
203 ein caused a shift in CD40 signaling through TNF receptor-associated factors (TRAF), including the TR
204 ransformation, binds tumour necrosis factor (TNF) receptor associated factor (TRAF) 1 and TRAF3 and t
205 e that IHPK2 binds to tumor necrosis factor (TNF) receptor-associated factor (TRAF) 2 and interferes
207 g by deubiquitinating tumor necrosis factor (TNF) receptor-associated factor (TRAF) 2, TRAF6, and NEM
208 ction is initiated by tumor necrosis factor (TNF) receptor-associated factor (TRAF) adapter proteins,
210 nd is a member of the tumor necrosis factor (TNF) receptor-associated factor (TRAF) family of putativ
213 -kappaB, and binds to tumor necrosis factor (TNF)-receptor-associated factor (TRAF) proteins, but the
214 s on the ubiquitin-conjugating enzyme Ubc13, TNF receptor-associated factor TRAF2, the protein kinase
218 JNK) pathways through their interaction with TNF receptor-associated factors (TRAFs) and NF-kappaB-in
219 F) family receptor in its ability to recruit TNF receptor-associated factors (TRAFs) and TNF receptor
221 , the most recently identified member of the TNF receptor-associated factors (TRAFs) family of protei
222 mily members, including CD40, is mediated by TNF receptor-associated factors (TRAFs) that interact wi
223 its ligand initiates signaling by recruiting TNF receptor-associated factors (TRAFs) to the CD40 cyto
224 are believed to be mediated in part through TNF receptor-associated factors (TRAFs), a family of cyt
225 lecule CD40 and its signaling intermediates, TNF receptor-associated factors (TRAFs), in diet-induced
226 The CD30 cytoplasmic tail interacts with TNF receptor-associated factors (TRAFs), which have been
232 in part, by engaging tumor necrosis factor (TNF) receptor-associated factors (TRAFs), which also med
235 these bacteria resulted in the activation of TNF receptor associated factors, two recently described